PTP4A3 and triple-negative breast carcinoma: Similar to our present findings, Gari et al found that inhibition of PRL-3 by shRNA or an inhibitor (Ampi-109), inactivated Src by reducing the phosphorylation of Y416 in triple-negative breast cancer [34].